Axcelis Technologies (ACLS) vs CRISPR Therapeutics (CRSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Axcelis Technologies (ACLS) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 58.0% versus a loss of 34.3%. Over five years, ACLS leads with a +170.4% price change compared with -48.0% for CRSP. CRISPR Therapeutics is the larger company by market cap ($4.88 billion vs $4.12 billion), about 1.2 times the size, while Axcelis Technologies is growing revenue faster (-17.6% vs -90.6%).
Axcelis Technologies converts more of its revenue into profit, with a net margin of 14.3% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACLS | CRSP |
|---|---|---|
| Share price | $133.48 | $50.44 |
| Market cap | $4.12B | $4.88B |
| 1-day change | -3.55% | -3.65% |
| YTD return | +66.14% | -3.81% |
| 1-year return | +58.02% | -34.31% |
| 5-year return | +170.37% | -48.00% |
| P/E ratio (TTM) | 44.79 | — |
| Forward P/E | 25.34 | — |
| EPS (TTM) | $2.98 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $839.05M | $3.51M |
| Revenue growth (YoY) | -17.57% | -90.59% |
| Net income (latest FY) | $120.24M | $-581.60M |
| Gross margin | 44.91% | — |
| Operating margin | 14.22% | -18933.65% |
| Net margin | 14.33% | -16569.77% |
| 52-week high | $193.78 | $78.38 |
| 52-week low | $73.60 | $44.12 |
| Distance from 52-week high | -31.12% | -35.65% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +20.62% | +73.59% |
| Average volume | 369.34K | 1.59M |
| Shares outstanding | 30.88M | 96.69M |
| Employees | 1,465 | — |
| Sector | Technology | Health Care |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACLS has outperformed CRSP by 92.3 percentage points over the past year.
- Axcelis Technologies is more profitable, keeping 14.3 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- Axcelis Technologies grew revenue faster in its latest fiscal year (-17.57% vs -90.59%).
- The two companies sit in different sectors: Axcelis Technologies in Technology and CRISPR Therapeutics in Health Care.
About Axcelis Technologies
ACLS stock →Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific.
Technology · Industrial Machinery/Components · 1,465 employees
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ACLS vs CRSP FAQ
Which is bigger, Axcelis Technologies or CRISPR Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $4.88B compared with $4.12B for Axcelis Technologies (ACLS).
Which stock has performed better over the past year, ACLS or CRSP?
ACLS returned +58.02% over the past 12 months, compared with -34.31% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are Axcelis Technologies and CRISPR Therapeutics in the same industry?
No. Axcelis Technologies is in the Technology sector, while CRISPR Therapeutics is in Health Care.